title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Univariate and multivariate COX regression analyses | MCC | MCC | The 6107 MCC patients included in this study were randomly divided into two groups in the ratio of 7:3 using R software (version 4.1.3). Data for patients in the training set were used to build the nomograms ( | PMC10620318 |
Construction of prognostic nomogram | Demographic variables (race, gender, age) and indicators with | PMC10620318 | ||
Result | PMC10620318 | |||
Patient characteristics | A total of 6107 COCA patients were obtained from the SEER database. Of these, 4276 were classified into the training cohort and 1831 in the validation group. Of the patients in the training cohort, 488 patients (11.4%) in the training cohort were < 50 years old, the majority (75.9%) were white, while the rest were blac... | PMC10620318 | ||
Univariate and multivariate COX regression analysis | tumor | BRAIN METASTASIS, TUMOR, PRIMARY TUMOR, LUNG METASTASIS, BONE METASTASIS, REGRESSION, LIVER METASTASIS | Firstly, one-way COX regression analysis for age, race, gender, tumor primary site, tumor size, TNM stage of the 8th edition of AJCC, serum carcinoembryonic antigen, nerve invasion, lymph node metastasis, liver metastasis, lung metastasis, bone metastasis, and brain metastasis were performed. Several factors, including... | PMC10620318 |
Prognostic nomogram construction | Nomograms for predicting 6 and 18 months of OS of COCA were constructed using data for patients in the training set (Fig. Nomograms for predicting the OS of COCA patients. | PMC10620318 | ||
Nomogram calibration and validation | The C-index was used to compare the performance of the nomograms. Particularly, the C-index of the training cohort without stratification by age and the validation cohort was 0.79 (95% CI 0.77–0.81) and 0.81 (95% CI 0.77–0.84), respectively. In the early-onset COCA training set cohort, validation cohort C-index was 0.9... | PMC10620318 | ||
Survival analyses | The overall risk scores (with the median score as the critical value) of each prognostic factor included in the three nomograms were calculated, and patients were divided into low-risk and high-risk groups. The KM curves were plotted (Fig. The KM curves for OS prediction of the TNM staging system. | PMC10620318 | ||
Discussion | cancer, deaths | CANCER | COCA is the fifth leading cause of cancer-related deaths worldwide (Sung et al. The dataset not stratified by age in this study is one in which the study cohort was not grouped based on age. Many previous studies have demonstrated that for cancer patients, older adults have a shorter OS survival than their younger oppo... | PMC10620318 |
Author contributions | All authors contributed to the research design. YZY designed and prepared the manuscript; YZY and PX performed the analysis, and CZ read and approved the final manuscript. | PMC10620318 | ||
Funding | This study was supported by Minsheng Science and Technology Program Joint Program (2021JH2/10300106). | PMC10620318 | ||
Data availability statement | The dataset supporting the conclusions of this paper is included in the material of this paper. | PMC10620318 | ||
Declarations | PMC10620318 | |||
Conflict of interest | The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. | PMC10620318 | ||
Ethics approval and consent to participate | Not applicable. | PMC10620318 | ||
Consent for publication | All authors consent to the publication of this study. | PMC10620318 | ||
References | PMC10620318 | |||
Key Points | PMC10570919 | |||
Question | SOFT TISSUE SARCOMA, STS | Is intratumoral toll-like receptor 4 agonist glycopyranosyl lipid A in stable-emulsion formulation (GLA-SE) injection with radiotherapy an effective and feasible treatment for patients with advanced soft tissue sarcoma (STS)? | PMC10570919 | |
Findings | tumors | TUMORS, STS | In this phase 1 nonrandomized controlled trial of 12 patients with advanced STS, intratumoral GLA-SE with radiotherapy was well tolerated, with all patients achieving local control of injected tumors. Durable local response was associated with expansion of intratumoral T-cell receptor clones, and these specific clones ... | PMC10570919 |
Meaning | T-cell | SOFT TISSUE SARCOMA | These findings suggest that intratumoral IT GLA-SE with radiotherapy is a promising combination treatment associated with systemic expansion of putative antitumor T-cell clones in advanced STS.This nonrandomized controlled trial of patients with advanced soft tissue sarcoma analyzed the immunomodulatory effects of intr... | PMC10570919 |
Importance | SOFT TISSUE SARCOMAS | Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options, and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist glycopyranosyl lipid A in stable-emulsion formulation (GLA-SE) has been studied as immunotherapy in other ... | PMC10570919 | |
Objective | STS | To evaluate the safety, efficacy, and immunomodulatory effects of IT GLA-SE with concurrent radiotherapy in patients with metastatic STS with injectable lesions. | PMC10570919 | |
Design, Setting, and Participants | sarcoma | SARCOMA, STS | This phase 1 nonrandomized controlled trial of patients with STS was performed at a single academic sarcoma specialty center from November 17, 2014, to March 16, 2016. Data analysis was performed from August 2016 to September 2022. | PMC10570919 |
Interventions | Two doses of IT GLA-SE (5 μg and 10 μg for 8 weekly doses) were tested for safety in combination with concurrent radiotherapy of the injected lesion. | PMC10570919 | ||
Main Outcomes and Measures | Primary end points were safety and tolerability. Secondary and exploratory end points included local response rates as well as measurement of antitumor immunity with immunohistochemistry and T-cell receptor (TCR) sequencing of tumor-infiltrating and circulating lymphocytes. | PMC10570919 | ||
Results | REGRESSION, ADVERSE EVENT | Twelve patients (median [range] age, 65 [34-78] years; 8 [67%] female) were treated across the 2 dose cohorts. Intratumoral GLA-SE was well tolerated, with only 1 patient (8%) experiencing a grade 2 adverse event. All patients achieved local control of the injected lesion after 8 doses, with 1 patient having complete r... | PMC10570919 | |
Conclusions and Relevance | In this nonrandomized controlled trial, IT GLA-SE with concurrent radiotherapy was well tolerated and provided more durable local control than radiotherapy alone. Patients with durable local response demonstrated enhanced IT T-cell clonal expansion, with matched expansion of these clonotypes in the circulation. Additio... | PMC10570919 | ||
Trial Registration | ClinicalTrials.gov Identifier: | PMC10570919 | ||
Introduction | cancers | SOFT TISSUE SARCOMA, CANCERS, NEOPLASMS, STS | Soft tissue sarcomas (STSs) are a heterogeneous group of more than 50 distinct mesenchymal neoplasms together composing 1% of all cancers. Despite incremental advances, median overall survival for patients with metastatic STS remains approximately 24 months.As a key exploratory end point, we characterized changes in th... | PMC10570919 |
Methods | PMC10570919 | |||
Study Design and Patients | tumor, sarcoma, hematologic, kidney, and hepatic function, Hutchinson Cancer, Cancer | SARCOMA, TUMOR, CANCER | This open-label, phase 1 nonrandomized controlled trial of IT GLA-SE was conducted at the Seattle Cancer Center Alliance and Fred Hutchinson Cancer Research Center from November 17, 2014, to March 16, 2016, in accordance with International Conference on Harmonization Guidelines for Good Clinical Practice and the Eligib... | PMC10570919 |
Treatment | tumor | TUMOR | Patients received planned, standard-of-care palliative radiotherapy to the injected superficial tumor as part of normal clinical care. Radiation was given within 2 weeks after starting GLA-SE injections. Although the goal radiation dose was 50 Gy or higher, the administered dose was at the discretion of the treating ra... | PMC10570919 |
Clinical Assessments | Tumors, tumor | TUMORS, ADVERSE EVENT, SYSTEMIC DISEASE, TUMOR | The primary objective was to assess the safety and tolerability of IT GLA-SE in combination with radiotherapy using the Common Terminology Criteria for Adverse Events, version 5.0. Secondary objectives were to assess the clinical efficacy of local and systemic disease control as well the immunologic effects. Assessment... | PMC10570919 |
TLR4 Staining Analysis | tumor | TUMOR | Slides from the formalin-fixed paraffin-embedded tumor blocks were stained with hematoxylin-eosin and with antibodies to TLR4 (MAB14783; R&D Systems) and analyzed by Mosaic Laboratories. A pathologist confirmed tumor presence using hematoxylin-eosin, and immunohistochemical findings were scored on a positivity scale of... | PMC10570919 |
Immunologic Correlative Studies | Rapid expansion protocol of TILs, | PMC10570919 | ||
Statistical Analysis | Statistical analysis was conducted from August 2016 to September 2022. All enrolled patients who received at least 1 dose of IT GLA-SE were included in the safety analysis. Descriptive statistics were used to summarize baseline patient characteristics, safety, clinical response, and immunologic response variables. Loca... | PMC10570919 | ||
Results | PMC10570919 | |||
Patients | sarcoma, synovial sarcoma, tumor | TUMOR, DISEASE, SARCOMA, SYNOVIAL SARCOMA, LEIOMYOSARCOMA | Twelve patients (median [range] age, 65 [34-78] years; 8 [67%] female and 4 [33%] male; 9 [75%] White, 1 [8%] Asian, and 2 [17%] with no race or ethnicity reported) with metastatic sarcoma with a superficial tumor amenable to bedside IT injection concurrent with radiotherapy given over 2 weeks were enrolled in the tria... | PMC10570919 |
Patient Characteristics at Baseline | myalgia, fatigue, infections, pain, rashes | ONCOLOGY, ADVERSE EVENT, INJECTION SITE REACTION, INFECTIONS | Abbreviation: ECOG, Eastern Cooperative Oncology Group.Data are presented as number (percentage) of patients unless otherwise indicated.Seven patients (58%) had at least a grade 1 adverse event (AE), with only 1 patient (8%) in the 5-μg cohort having grade 2 AEs (myalgia and fatigue). The most common AE reported was fa... | PMC10570919 |
Number of Patients With TRAEs | ADVERSE EVENTS, ADVERSE EVENT, ADVERSE EVENT | Abbreviation: TRAE, treatment-related adverse event.Grading of adverse events was based on Common Terminology Criteria for Adverse Events, version 5.0. | PMC10570919 | |
Local Response | tumor, sarcoma | TUMOR, SARCOMA | All patients achieved local control of the injected target lesions after 8 doses. One patient (8%) had complete response in the injected tumor, whereas 4 other patients (33%) had durable local response with greater than 25% size reduction. In this small cohort, there was no apparent association between local response a... | PMC10570919 |
Local Response of Lesions Receiving Intratumoral Glycopyranosyl Lipid A in Stable-Emulsion Formulation | tumor | DISEASE, TUMOR, BEST | A, Spider plot demonstrating change from baseline of tumor size and its durability beyond the trial period. B, Best percent change (which was at the end of follow-up time point for all patients) by cohort and histologic subtype.To analyze the contribution of IT GLA-SE in combination therapy, we identified 3 patients wi... | PMC10570919 |
Local Control After Intratumoral Glycopyranosyl Lipid A in Stable-Emulsion Formulation (IT GLA-SE) Compared With Concomitant Lesions | tumor, tumors, leiomyosarcoma | TUMOR, TUMORS, LEIOMYOSARCOMA, REGRESSION, UNDIFFERENTIATED ROUND CELL SARCOMA | A, Percent change in size of lesions at end of same follow-up period for tumors receiving IT GLA-SE plus radiotherapy (orange) vs tumors receiving radiation only (blue) or no local treatment (green). B, Representative computed tomograms of lesions at baseline and at last follow-up in a patient with undifferentiated rou... | PMC10570919 |
Changes in the Tumor Microenvironment of Injected Tumor | Where sufficient quality tissue was available for evaluation of spatial architecture (n = 7), multiplex immunohistochemical analysis was performed on pretreatment and posttreatment samples ( | PMC10570919 | ||
Local Immune Infiltration After Intratumoral Glycopyranosyl Lipid A in Stable-Emulsion Formulation (IT GLA-SE) in Durable Responders | tumor, sarcomas | HEAT, TUMOR, INFILTRATION, SARCOMAS | A, Multiplex immunohistochemical analysis found a detectable increase in CD4 and CD8 T-cell infiltration after treatment with IT GLA-SE. One patient had a detectable increase in CD4 T-cell infiltration from 11% to 34% of all cells counted, in addition to an increase in CD8 infiltration from 0.3% to 3.4%. Another patien... | PMC10570919 |
Changes to TCR Repertoire in TILs Following GLA-SE | inflammation, tumor | INFLAMMATION, TUMOR, INFILTRATION | To delineate whether the increased T-cell infiltration was due to a generalized inflammation vs clonal expansion against putative tumor antigens, we analyzed TILs, generated from core biopsy samples and expanded ex vivo, using TCR sequencing. In total, 10 patients had evaluable TILs from both pretreatment and posttreat... | PMC10570919 |
Circulating T-Cell Response | inflammation, tumor, tumor necrosis, death | REGRESSION, INFLAMMATION, TUMOR, TUMOR NECROSIS | We were interested in whether TCR sequences dominant in TILs became more prevalent in the circulation as part of a systemic antitumor response. The PBMCs from all patients underwent TCR sequencing before and after completion of study treatment. Of particular interest was 1 patient who had a complete local response with... | PMC10570919 |
Discussion | METASTASIS | Radiation therapy is an effective tool in the management of symptomatic metastasis for STS.We saw large increases in the clonality of PBMCs, including expansion of TCR sequences observed in TILs, suggesting additional systemic potential for this therapy. | PMC10570919 | |
Limitations | This study as some limitations. Because this was a phase 1 dose-escalation trial, the findings are preliminary. In addition, the number of patients was limited and not powered to evaluate clinical efficacy, and there was no placebo control group. | PMC10570919 | ||
Conclusions | tumor | TUMOR | In this phase 1 nonrandomized controlled trial, IT GLA-SE with concurrent radiotherapy was safe, with preliminary evidence of efficacy in the injected tumor. However, further study is warranted. In patients with durable local response, there was evidence of intratumoral T-cell clonal expansion of both preexisting and n... | PMC10570919 |
Background | fractures, intertrochanteric fracture, pain | Hip fractures are common in elderly patients. The surgery is usually delayed due to underlying conditions, and pain control is crucial while the patient is cleared for surgery. In this randomized controlled trial (RCT) study, we hypothesized that the application of skin traction in patients with intertrochanteric fract... | PMC9834036 | |
Methods | fractures, drug addiction, swelling | SKIN | This is a prospective, single institution, parallel randomized controlled trial. Two hundred and twenty-nine patients with isolated intertrochanteric fractures were enrolled in the study. Patients with neurologic issues, drug addiction, scars or swelling, or vascular issues at the site of skin traction application were... | PMC9834036 |
Results | fractures, postoperative delirium | After excluding patients with postoperative delirium, 154 patients (55 males and 99 females) with isolated intertrochanteric fractures (69 right-sided and 85 left-sided), and a mean age of 70 ± 10 remained in the study. There were no significant differences between the two groups regarding age, gender, and mean time fr... | PMC9834036 | |
Conclusion | fractures, intertrochanteric fractures | Pre-operative skin traction application affected neither the patients' VAS scores nor the mean morphine dosage per day in patients with isolated intertrochanteric fractures. Our data does not support the routine application of pre-operative skin traction in patients with intertrochanteric fractures. | PMC9834036 | |
Trial registration | The project was registered in the Iranian Registry of Clinical Trials (registration reference: IRCT20180729040636N3, registration date: 01/07/2020). | PMC9834036 | ||
Level of evidence | 1. | PMC9834036 | ||
Keywords | PMC9834036 | |||
Background | delirium, tractions, pain, fractures, trauma | COMPLICATIONS | Hip fractures are common in orthopedic trauma, and current practice and literature suggests improved outcomes with early operation [In addition, patients with severe pain during hospitalization are at higher risk for experiencing delirium and other post-operative complications [Wennberg et al. reported that supplementa... | PMC9834036 |
Methods | fracture, postoperative delirium, intertrochanteric fractures, pain | SECONDARY, COMPLICATIONS | This randomized controlled trial is designed, conducted, and written based on the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement [Patients who consented to the study (192 patients) were then randomized to two groups by a medical student (S.KH.) who used random allocation software with an allocation... | PMC9834036 |
Discussion | allergy, tamponade, AVN, DVT, occlusion of the vascular, fracture, pulmonary suppression, intertrochanteric fractures, femoral neck fractures, hip fracture, thromboembolic, avascular necrosis, femur fractures, fractures, intertrochanteric hip fractures, delirium, pain, constipation, femoral fractures, collum femoris fr... | INTRAOPERATIVE COMPLICATIONS, STILL, ALLERGY, COMPLICATION, AVASCULAR NECROSIS, PRESSURE ULCERS, UTI, DECUBITUS ULCERS, DISEASES, COMPLICATIONS, DVT | In our study, no significant difference was found in VAS score values and the mean morphine dosage administered per day between the patients with intertrochanteric fractures who underwent skin traction and the control group without traction. Therefore, in terms of pain alleviation, applying skin traction for these pati... | PMC9834036 |
Conclusion | fractures, ’ pain, intertrochanteric hip fractures | In conclusion, in our research, skin traction application affected neither the patients’ mean VAS scores nor the mean morphine dosage administered daily in patients with isolated intertrochanteric fractures. Considering the limited hospital time and resources and its burden on both patients and medical staff, we recomm... | PMC9834036 | |
Acknowledgements | Not applicable. | PMC9834036 | ||
Authors' contributions | All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Hossein Akbari Aghdam, Mehdi Motififard, Navid Gharib Gashteh Shahi, Mohammad Saleki Mehrjardi, Tayebe Rezaei, and Sara Kheiri. The first draft of the manuscript was written by Sara Kheiri an... | PMC9834036 | ||
Funding | This study was not funded by any individual or any organizations. | PMC9834036 | ||
Availability of data materials | The datasets generated and/or analyzed during the current study are not publicly available due to patients’ privacy but are available from the corresponding author on reasonable request. | PMC9834036 | ||
Declarations | PMC9834036 | |||
Ethics approval and consent to participate | The study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the research ethics committee of Isfahan University of Medical Sciences. The project was registered in the Iranian Registry of Clinical Trials (registration reference: IRCT20180729040636N3, registratio... | PMC9834036 | ||
Consent for publication | Not applicable. | PMC9834036 | ||
References | The authors declare that they have no conflict of interest/ competing interests. | PMC9834036 | ||
Background | depression, anxiety | Collaborative care (CC) could improve outcomes in primary care patients with common mental conditions. We assessed the effectiveness of a transdiagnostic model of telephone-based CC (tCC) delivered by lay providers to primary care patients with depression, anxiety, or at-risk drinking. | PMC10517649 | |
Methods | depression, anxiety, depressive symptoms | PCP | PARTNERS was a pragmatic trial in 502 primary care adults presenting with depressive symptoms, anxiety symptoms, or at-risk drinking randomized to (1) usual care by primary care providers (PCPs) enhanced with the results of computer-assisted telephone-based assessments (at baseline and 4, 8, and 12 months later) (enhan... | PMC10517649 |
Results | depression, anxiety | There were no treatment or time×treatment effects between tCC and eUC on PHQ-9 scores for patients with depression during the 12-month follow-up. However, there was a treatment effect (tCC > eUC) on GAD-7 scores in those with anxiety and a time×treatment interaction effect on the number of weekly drinks (tCC > eUC) in ... | PMC10517649 | |
Conclusion | depression, anxiety | DISORDERS | Implementing transdiagnostic tCC for common mental disorders using lay providers appears feasible in Canadian primary care. While tCC was not better than eUC for depression, there were some benefits for those with anxiety or at-risk drinking. Future studies will need to confirm whether tCC differentially benefits patie... | PMC10517649 |
Abrégé | PMC10517649 | |||
Contexte | d’anxiété ou à risque de consommation d'alcool | Les soins collaboratifs (SC) pourraient améliorer les résultats chez les patients des soins de première ligne souffrant d’états mentaux communs. Nous avons évalué l’efficacité d’un modèle transdiagnostique de SC par téléphone (SCt) dispensé par des prestataires non professionnels à des patients de première ligne souffr... | PMC10517649 | |
Méthodes | d’anxiété ou une consommation à risque | PARTNERS était un essai pragmatique mené auprès de 502 adultes recevants des soins de première ligne qui présentaient des symptômes dépressifs, d’anxiété ou une consommation à risque et qui ont été randomisés à : (1) des soins usuels par des prestataires de première ligne (PPL) améliorés par les résultats d’évaluations... | PMC10517649 | |
Résultats | Il n’y avait pas d’effet de traitement ou d'interaction temps par traitement entre SCt et eSU aux scores QSP-9 pour les patients souffrant de dépression durant le suivi de 12 mois. Cependant, il y avait un effet de traitement (SCt > eSU) aux scores TAG-7 chez ceux souffrant d’anxiété et un effet d’interaction temps par... | PMC10517649 | ||
Conclusion | d’anxiété ou à risque de consommation | Mettre en œuvre des SCt transdiagnostiques pour les troubles mentaux communs avec l’aide de prestataires non professionnels semble faisable dans les soins de première ligne canadiens. Bien que SCt n’ait pas mieux réussi que eSU pour la dépression, il y avait certains bénéfices pour ceux souffrant d’anxiété ou à risque ... | PMC10517649 | |
Introduction | Depression, disability, anxiety, chronic disease | CHRONIC DISEASE | Depression, anxiety, and at-risk drinking are leading causes of disability worldwide.Collaborative care (CC) is a complex intervention based on the chronic disease management model. | PMC10517649 |
Methods | comorbidity, posttraumatic stress disorder, anxiety, cognitive impairment, bipolar disorder, psychotic disorders, depression, obsessive–compulsive disorder | DISORDER, RECRUITMENT, REGRESSIONS, ADVERSE EFFECTS, SECONDARY, REMISSION, BLIND, PCP, REGRESSION | The methods of the study have been publishedAll participants were recruited in primary care clinics in urban areas, suburban locations, and rural areas across Ontario (Canada) with all study activities conducted remotely by phone from a central office in Toronto. All participants signed an informed consent form approve... | PMC10517649 |
Primary and Secondary Outcomes in Each Diagnostic Group | SE | For the primary clinical outcome (i.e., change in PHQ-9 scores in participants with a PHQ-9 score of ≥10 at baseline), the test for the contrast between the two treatment groups was not significant (mean (SE) difference between treatment groups in change in PHQ-9 score from baseline to 12 months: −0.19 (0.66); PHQ-9 sc... | PMC10517649 | |
Initiation or Change in Antidepressant Treatment | The review of health records showed higher rates of documentation of initiation of antidepressants (Fisher's | PMC10517649 | ||
Quality of Life and Functioning in the Whole Sample | There was a significant time effect for VR-12 mental scores ( | PMC10517649 | ||
Response and Remission Rates | depression, Depression, Anxiety, anxiety | EVENT, REMISSION, REGRESSION, EVENTS, RESOLUTION | Inferential results related to logistic regression modelling of response and remission rates are presented in Rates (Denominator/Numerator) of Response or Remission for Depression, or Anxiety, and Resolution of At-Risk Drinking.Comparison of Rates of Response or Remission for Depression, or Anxiety, and Resolution of A... | PMC10517649 |
Discussion | anxiety, psychiatric, depressive symptoms, depression, adjustment disorders | DISORDER, REMISSION, PCP | In this RCT of over 500 primary care patients with symptoms of depression, anxiety, or at-risk drinking, compared with eUC, a novel, low-cost, transdiagnostic tCC intervention delivered by lay providers did not result in a larger improvement in depression symptoms in those presenting with depression at baseline or in h... | PMC10517649 |
Supplemental Material | PMC10517649 | |||
sj-docx-1-cpa-10.1177_07067437231156243 - Supplemental material for A Collaborative-Care Telephone-Based Intervention for Depression, Anxiety, and at-Risk Drinking in Primary Care: The PARTNERs Randomized Clinical Trial | Depression, Anxiety, P. | MITCHELL | Click here for additional data file.Supplemental material, sj-docx-1-cpa-10.1177_07067437231156243 for A Collaborative-Care Telephone-Based Intervention for Depression, Anxiety, and at-Risk Drinking in Primary Care: The PARTNERs Randomized Clinical Trial by M. Ishrat Husain, David J. Rodie, Athina Perivolaris, Marcos S... | PMC10517649 |
References | PMC10517649 | |||
Background | hypertension, weight loss | HYPERTENSION | Edited by: Paul H. Lee, University of Southampton, United KingdomReviewed by: Arkers Kwan Ching Wong, Hong Kong Polytechnic University, Hong Kong SAR, China; Weidan Cao, Washington State University, United StatesThis article was submitted to Public Health Education and Promotion, a section of the journal Frontiers in P... | PMC10014612 |
Methods | hypertension | HYPERTENSION | In this parallel-group, randomized controlled trial, we recruited individuals from health-care centers, home visits, and community centers in low-resource rural settings in Hubei, China. Of 200 participants who were screened, 148 completed consent, met inclusion criteria, and were randomly assigned in a ratio of 1:1 to... | PMC10014612 |
Results | Participants ( | PMC10014612 | ||
Conclusions | hypertension, weight loss | UNCONTROLLED HYPERTENSION, HYPERTENSION | Among participants with uncontrolled hypertension, individuals randomized to use a monitoring wearable device with a smartphone application had a significant improvement in self-reported hypertension compliance, self-efficacy, life quality, weight loss and diastolic blood pressure, but no change in systolic blood press... | PMC10014612 |
Introduction | hypertension, weight loss, Hypertension, cardiovascular and cerebrovascular events | CHRONIC DISEASES, CARDIOVASCULAR DISEASE, HYPERTENSION, HYPERTENSION | Hypertension is the most common chronic condition for cardiovascular and cerebrovascular events worldwide, affecting 32.6% of US adults, and has an estimated annual medical expenses exceeding $50 billion (Many types of intervention methods have been conducted to improve therapeutic targets and BP control. Systematic re... | PMC10014612 |
Methods | PMC10014612 | |||
Study design | Hypertension, hypertensive | RECRUITMENT, HYPERTENSION | The Self-Monitoring Intervention Programme for Hypertension Control was a randomized trial conducted among 6 primary care centers within a remote mountainous districts of Hubei province, China. Details of the Program's study design and organizations have been published elsewhere (All the selected primary care centers w... | PMC10014612 |
Conceptual framework | We adopted an integrating of constructs adapted from the following conceptual models: the Task-Technology Fit (Conceptual framework for designing mHealth solutions. | PMC10014612 | ||
Study population | death, cognitive deficit, cognitive dysfunction | HYPERTENSION | Eligibility criteria were an age of more than forty, definite diagnosis of hypertension: Systolic blood pressure (SBP) ≥140 mmHg and/or Diastolic blood pressure (DBP) ≥90 mmHg or being treated with antihypertensive medication, no cognitive deficit and able to possess communication proficiency to carry out study tasks. ... | PMC10014612 |
Patient recruitment and randomization | EVENTS | Participants were recruited though the cooperation of local Health and Family Planning Committee (HFPC), which composed of a diverse group of community leaders, township health centers personnel. These cooperative relationships were maintained with regular health advocacy meetings, face-to-face contact, and HFPC events... | PMC10014612 | |
Intervention | hypertension | HYPERTENSION | The mobile health intervention was the key element, with a complementary text messaging, BP warning, and home-visited intervention. The research team members, who were part of the staff of the local primary care centers, were trained in interactive intervention techniques, performing wearable device, measuring BP, prov... | PMC10014612 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.